Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 3/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3161907 | 0.84 | ALDH1A1 (0.71) | ALDH1A1ALOX15HTTNPC1RAB9A | |
| SCHEMBL16866257 | 0.84 | ALDH1A1 (0.66) | ALDH1A1ALOX15HTTNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL27728003 | 0.83 | ALDH1A1 (0.69) | ALDH1A1ALOX15HTTNPC1RAB9A | |
| SCHEMBL19924516 | 0.83 | ALDH1A1 (0.69) | ALDH1A1ALOX15HTTNPC1RAB9A | |
| SCHEMBL5267380 | 0.83 | ALDH1A1 (0.68) | ALDH1A1ALOX15HTTNPC1RAB9A | |
| SCHEMBL3171559 | 0.81 | ALDH1A1 (0.67) | ALDH1A1ALOX15HTTNPC1RAB9A | |
| SCHEMBL6985088 | 0.81 | ALDH1A1 (0.67) | ALDH1A1ALOX15HTTNPC1RAB9A | |
| SCHEMBL827308 | 0.81 | ALDH1A1 (0.61) | ALDH1A1ALOX15HTTNPC1RAB9A | |
| SCHEMBL28065837 | 0.81 | ALDH1A1 (0.66) | ALDH1A1ALOX15HTTNPC1RAB9A | |
| SCHEMBL16005429 | 0.81 | ALDH1A1 (0.66) | ALDH1A1ALOX15HTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1966214-B1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-02 | — | — | EP | disclosed |
| US-8173654-B2 | Triazolopyridazine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8030305-B2 | Triazolopyridazines as kinase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-04 | — | — | US | disclosed |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| EP-0991624-B1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-11-19 | — | — | EP | disclosed |
| EP-0991624-A1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | Boehringer Ingelheim Pharma KG (DE) | 2000-04-12 | — | — | EP | disclosed |
| EP-0682017-B1 | Substituted bicycle heteroaroylguanidines, their preparation and their application in medicaments and diagnostic agents | HOECHST AG (DE) | 1999-08-11 | — | — | EP | disclosed |
| WO-1999000371-A1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-01-07 | — | — | WO | disclosed |
| EP-0682017-A1 | Substituted bicycle heteroaroylguanidines, their preparation and their application in medicaments and diagnostic agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | ALDH1A1 1429/4885ALOX15 4241/4885HTT 3089/4885 |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | ALDH1A1 1429/4885ALOX15 4241/4885HTT 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.